Contraceptive Counseling for the Immediate Postpartum Period
ACOG disclaimer

This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on www.acog.org or by calling the ACOG Resource Center.

While ACOG makes every effort to present accurate and reliable information, this publication is provided "as is" without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

© 2019 by the American College of Obstetricians and Gynecologists, 409 12th Street SW, PO Box 96920, Washington, DC 20090-6920. Individuals and groups providing patient care or clinical education in family planning have permission to copy all or any portion of this slide set for noncommercial, educational purposes, provided that no modifications are made and proper attribution is given.
Speaker disclosures

• [Presenter to add any financial disclosures here]
Topics covered in presentation

Section 1: Unmet patient need for postpartum contraception
Section 2: Contraceptive counseling with shared medical decision-making framework
Section 3: Clinical considerations*
Section 4: Breastfeeding & IUD expulsion
Section 5: Follow up instructions

* Note: The Food and Drug Administration requires all health care providers who perform implant insertions and removals receive training from the manufacturer. Therefore, the implant insertion process is not covered in this presentation.
Learning objectives

1. Understand the unmet contraceptive needs postpartum
2. Describe postpartum contraceptive methods currently available
3. Understand key elements of person-centered postpartum contraceptive counseling
4. Describe different methods and tools to engage in person-centered contraceptive counseling

©ACOG
UNMET PATIENT NEED

for Postpartum Contraception
The need for postpartum contraception

- The greatest risk of low birth weight and preterm birth occurs when the birth to conception interval is <6 months

- Data suggests a modest increase in risk of adverse outcomes associated with intervals of <18 months

- The optimal interval between delivery and subsequent pregnancy is 18 months to 5 years
Challenges with initiating postpartum contraception

Patients may have difficulty returning for a postpartum visit because of:

- Childcare obligations
- Unable to get off work
- Unstable housing
- No transportation
- Communication or language barrier
- Lack of insurance coverage or potential expiration of Medicaid eligibility
Challenges with initiating postpartum contraception

- As many as 40% of women do not return for the 6 week postpartum visit
  - Even lower in under-resourced areas, further contributing to health disparities

- Non-breastfeeding women can ovulate as early as 25 days postpartum
  - 40% of women will ovulate by 6 weeks postpartum

- 57% of women are sexually active by 6 weeks postpartum
LARC can serve as a bridge method to tubal ligation

• At least 1/3 of women who want a postpartum tubal ligation will not have it done

• 47% of women discharged without having a desired postpartum tubal ligation will be pregnant within 1 year

• Issues preventing tubal ligation at the time of delivery:
  o Insurmountable systems barriers like lack of an operating room, physician availability, or incomplete consent forms
  o Insurance Issues
    ▪ Medicaid coverage may end postpartum
    ▪ Uninsured – cost of sterilization can be prohibitive

• Immediate postpartum LARC can serve as a bridge method for those unable to get a desired tubal ligation

©ACOG
What is LARC?

• LARC stands for long-acting reversible contraception

• 2 types of LARC: the intrauterine device and the contraceptive implant, which are the most effective reversible forms of contraception

• **Advantages** of LARC include:
  1. Methods do not require ongoing effort for long-term and effective use
  2. Rapid return to fertility after removal of the device

• **Disadvantage:** must be placed and removed by a trained clinician, which impacts patient autonomy
What is immediate postpartum LARC?

LARC methods are available to women in the hospital after a delivery before discharge

• ACOG, CDC, WHO, and Cochrane Reviews all support immediate postpartum LARC as a safe and effective option

• Can be an ideal time to provide LARC methods for many women who want them
Definitions: timing of LARC placement

1. **Immediate postplacental** – placement while still in the delivery room and, when possible, within 10 minutes of placental delivery

2. **Immediate postpartum** – placement during hospital admission for delivery

3. **Postpartum** – placement within 6 weeks of delivery

4. **Interval placement** – placement at any time during the menstrual cycle and not in relationship to the end of a pregnancy (or >6 weeks after delivery)
IPP LARC satisfaction & continuation rates

• Many women like and continue using their immediate postpartum LARC method
  o 74% of women who had an IUD placed immediately postpartum had their IUD in place at one year
  o 84% of women who had an implant placed immediately postpartum still had the implant at one year

• Elective discontinuation for IUDs and implants are similar with interval placement
IPP LARC can help meet patients’ needs

- Safe
- Convenient
- Highly effective
- Reversible
- Forgettable
- High continuation rates
CONTRACEPTIVE COUNSELING

Shared Medical Decision Making
Contraceptive coercion

• Contraceptive coercion is the act of pressuring or forcing an individual to use a method of birth control that they do not desire

• The U.S. has a long history of contraceptive coercion and forced sterilization perpetrated against economically marginalized individuals and persons of color.
Forced Sterilization

• The Eugenics movement of the early 1900s

• Continued forced or coerced sterilization through 1970’s of the economically marginalized, those with mental illnesses, persons of color, and immigrant individuals
  - Population control
  - Social control
  - Form of punishment
  - Extortion to ensure receipt of public assistance
  - Trainee education

• Recent cases in the 2000s in California prisons
Reproductive Injustices

- Mississippi Appendectomy
- Indian Health Services
- La Operación
- Oral contraception clinical trials
- Norplant and Depo Provera
Contraceptive counseling, especially on sterilization or LARC methods, must be sensitive to this history.
Reproductive justice

SisterSong defines reproductive justice as:

“The human right to maintain personal bodily autonomy, have children, not have children, and parent the children we have in safe and sustainable communities.”

- SisterSong Women of Color Reproductive Justice Collective
A reproductive justice framework for contraceptive counseling

Key Takeaway:

“The framework of reproductive justice connects family planning and other aspects of sexual and reproductive health with the disparities and complexities that affect patients’ lives. Furthermore, it encourages gynecologic health care providers to examine issues of bias and coercion and advocate for equitable access and change.”

- ACOG Committee Opinion #699, Adolescent Pregnancy, Contraception, and Sexual Activity
Provider bias

• **Explicit bias**: a bias that a person is aware of and believes is correct in some manner

• **Implicit bias**: a bias that is unintentional and unconscious but is activated quickly and unknowingly by situational factors

• **Implicit association tests**: [https://implicit.harvard.edu/implicit/](https://implicit.harvard.edu/implicit/)

• **Consequences on patient-provider relationship include**:
  - Rapid discontinuation of methods that client felt pressured to select
  - Delaying future healthcare access and contraceptive use due to previous negative encounters
  - Undermining trust and decreased receptiveness to contraceptive counseling

Slide courtesy of Dr. Serina Floyd

©ACOG
Shared medical decision making for contraceptive counseling

- **When engaging in shared medical decision making:**
  - Be aware of and address your own biases
  - Practice perspective-taking and individuation when caring for each person
  - Acknowledge historical racial injustices during counseling sessions
  - Strive for equitable outcomes for all people, especially for disadvantaged or marginalized groups.

©ACOG

Talking with patients about contraception

- Shared medical decision making is a process where both patients and clinicians share information, express treatment preferences, and agree on a treatment plan.

- It can increase patient engagement and reduce risk, resulting in improved outcomes, satisfaction, and treatment adherence.

- Although medical knowledge is tipped towards the provider, in shared medical decision making a middle ground is sought that incorporates accurate medical information and a patient’s personal preferences.

- Person-centered goals may also have a part in the decision-making process.

©ACOG


5 components of shared medical decision making

1. Focus on interpersonal relationship.
2. Elicit patient preferences for methods.
3. Be attuned to diverse patient preferences.
4. Provide relevant information in accordance with patient preferences.
5. Be aware of and responsive to patient preferences during counseling.

©ACOG
5 components of shared medical decision making

1. Focus on interpersonal relationship
Intimate, friend-like interactions establish trust and openness between providers and patients and are consistent with patient preferences for counseling about contraception.

   - Examples:
     - “Hi ____! It’s nice to see you again. How’s everything been since we saw each other last?”
     - “How are you liking the implant you received last time?”

2. Elicit patient preferences for methods
Open the discussion of contraceptive method options with an open-ended question that provides a clear indication that the patients’ preferences are the focus of the discussion.

   - Examples:
     - “What brings you to our office today?”
     - “What is important to you about your birth control method?”
3. Be attuned to diverse patient preferences
Patients will have varied preferences around issues including the relative importance of preventing pregnancy and the significance of specific side effects, including menstrual changes.

• Examples:
  o “It’s really important for me to continue having a monthly period, so it’s less obvious I’m using contraception.”
  o “I absolutely cannot gain any weight.”

4. Provide relevant information in accordance with patient preferences
Prioritize sharing information about methods based on what is most important to the patient, whether that is side effects, efficacy, mode of use, or other method characteristics.

• Examples:
  o “Since you said you want regular menses, you might consider oral contraceptive pills.”
  o “I hear you. The injectable contraceptive is the only method proven to cause weight gain, but every body reacts differently so we can work together to see which method works best for you.”
5 components of shared medical decision making

5. Be aware of and responsive to patient preferences during counseling
Either through direct questioning or by assessing her response to a shared decision making approach, understand and adjust counseling, and specifically the extent of provider guidance in the decision-making process according to how the patient would like decisions to be made.

- Examples:
  - “Do you want to use a method that you can easily start and stop on your own?”
  - “How do you feel about having to take a pill at the same time everyday? Does that fit into your daily life?”

Remember the goal! Be person-centered.
Video: Initiation of a shared decision-making process

LARC COUNSELING SCENARIOS:
Initiation of Shared Decision Making Process

©ACOG

Talking with patients about LARC

• Highlight the reliance on a provider for insertion/removal

• Be mindful that LARC can cause a decreased sense of control or the feeling of being pressured into a contraceptive method

• Discuss options for low or no-cost removal services, including Title X or other clinics

©ACOG

Immediate postpartum LARC counseling

- Optimally, patients should be counseled prenatally

- Counseling on immediate postpartum LARC should include:
  - **All** indicated forms of contraception
  - Advantages, contraindications, and alternatives
  - Increased risk of expulsion, including unrecognized expulsion of IUD
  - Convenience and effectiveness, as well as the benefits of reducing unintended pregnancy and lengthening interpregnancy intervals
  - A discussion on the theoretical risk of reduced duration of breastfeeding
  - Possibility of non-visualized strings and difficult removal

- More info & resources: ACOG Postpartum Contraceptive Access Initiative Website
Tools for contraceptive counseling

**Bedsider.org**

**U.S. MEC phone app**
Video: Shared decision making using a decision aid

LARC COUNSELING SCENARIOS:

Shared Decision Making Using a Decision Aid
Video: Responding to patient concerns

LARC COUNSELING SCENARIOS:

Responding to Patient Concerns
Video: Patient requesting implant removal

LARC COUNSELING SCENARIOS:

Patient Requesting Implant Removal

Trauma-informed care

Key Takeaway:

“This [trauma-informed care] framework can help optimize the patient–provider relationship, improve health outcomes, and reduce long lasting burdens of trauma.”

- ACOG Committee Opinion #777, Sexual Assault
CLINICAL CONSIDERATIONS

of Immediate Postpartum Contraception
Birth control options

- The Implant (Nexplanon)
- IUD (Skyla)
- IUD (Mirena)
- IUD (ParaGard)
- Sterilization, for men and women

- The Pill
- The Patch
- The Ring
- The Shot (Depo-Provera)

- Withdrawal
- Diaphragm
- Fertility Awareness
- Condoms, for men and women

©ACOG
<table>
<thead>
<tr>
<th>Method</th>
<th>Pregnancy Rate in 1 Year</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sterilization (female &amp; male)</td>
<td>0.5%, 0.15%</td>
<td>- Permanent</td>
</tr>
<tr>
<td>Etonogestrel (ENG) Implant</td>
<td>0.05%</td>
<td></td>
</tr>
<tr>
<td>IUD: Copper</td>
<td>0.8%</td>
<td></td>
</tr>
<tr>
<td>IUD: Levonorgestrel (LNG)</td>
<td>0.2%</td>
<td></td>
</tr>
</tbody>
</table>

©ACOG
<table>
<thead>
<tr>
<th>Method</th>
<th>Pregnancy Rate in 1 Year</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sterilization (female &amp; male)</td>
<td>0.5%, 0.15%</td>
<td>- Permanent</td>
</tr>
<tr>
<td>Etonogestrel (ENG) Implant</td>
<td>0.05%</td>
<td>- Must be placed and removed by trained clinician</td>
</tr>
<tr>
<td>IUD: Copper</td>
<td>0.8%</td>
<td>- Clinicians must attend manufacture training prior to placement</td>
</tr>
<tr>
<td>IUD: Levonorgestrel (LNG)</td>
<td>0.2%</td>
<td>©ACOG</td>
</tr>
<tr>
<td>Method</td>
<td>Pregnancy Rate in 1 Year</td>
<td>Special Considerations</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Sterilization (female &amp; male)</td>
<td>0.5%, 0.15%</td>
<td>- Permanent</td>
</tr>
<tr>
<td>Etonogestrel (ENG) Implant</td>
<td>0.05%</td>
<td>- Must be placed and removed by trained clinianan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Clinicians must attend manufacture training prior to placement</td>
</tr>
<tr>
<td>IUD: Copper</td>
<td>0.8%</td>
<td>- Must be placed and removed by trained clinianan</td>
</tr>
<tr>
<td>IUD: Levonorgestrel (LNG)</td>
<td>0.2%</td>
<td>- Must be placed and removed by trained clinianan</td>
</tr>
</tbody>
</table>

©ACOG
<table>
<thead>
<tr>
<th>Method</th>
<th>Pregnancy Rate in 1 Year</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable (Medroxyprogesterone acetate)</td>
<td>6%</td>
<td>- Must obtain injection every 3 months</td>
</tr>
<tr>
<td>Progestin-only pill (norethindrone)</td>
<td>9%</td>
<td></td>
</tr>
<tr>
<td>Estrogen/progestin combined pill, patch or ring</td>
<td>9%</td>
<td></td>
</tr>
<tr>
<td>Barrier Methods (condoms, diaphragm)</td>
<td>12-21%</td>
<td></td>
</tr>
<tr>
<td>Method</td>
<td>Pregnancy Rate in 1 Year</td>
<td>Special Considerations</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>--------------------------</td>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td>Injectable (Medroxyprogesterone acetate)</td>
<td>6%</td>
<td>- Must obtain injection every 3 months</td>
</tr>
<tr>
<td>Progestin-only pill (norethindrone)</td>
<td>9%</td>
<td>- Must take pill at same time every day with 3 hour late window</td>
</tr>
<tr>
<td>Estrogen/progestin combined pill, patch or ring</td>
<td>9%</td>
<td></td>
</tr>
<tr>
<td>Barrier Methods (condoms, diaphragm)</td>
<td>12-21%</td>
<td></td>
</tr>
<tr>
<td>Method</td>
<td>Pregnancy Rate in 1 Year</td>
<td>Special Considerations</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Injectable (Medroxyprogesterone acetate)</td>
<td>6%</td>
<td>- Must obtain injection every 3 months</td>
</tr>
<tr>
<td>Progestin-only pill (norethindrone)</td>
<td>9%</td>
<td>- Must take pill at same time every day with 3 hour late window</td>
</tr>
<tr>
<td>Estrogen/progestin combined pill, patch or ring</td>
<td>9%</td>
<td>- Must take pill at the same time every day, change patch every week, or ring every month.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Estrogen containing methods are contraindicated with some medical conditions, including immediately post-partum</td>
</tr>
<tr>
<td>Barrier Methods (condoms, diaphragm)</td>
<td>12-21%</td>
<td></td>
</tr>
<tr>
<td>Method</td>
<td>Pregnancy Rate in 1 Year</td>
<td>Special Considerations</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>--------------------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>Injectable (Medroxyprogesterone acetate)</td>
<td>6%</td>
<td>- Must obtain injection every 3 months</td>
</tr>
<tr>
<td>Progestin-only pill (norethindrone)</td>
<td>9%</td>
<td>- Must take pill at same time every day with 3 hour late window</td>
</tr>
<tr>
<td>Estrogen/progestin combined pill, patch or ring</td>
<td>9%</td>
<td>- Must take pill at the same time every day, change patch every week, or ring every month.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Estrogen containing methods are contraindicated with some medical conditions, including immediately post-partum</td>
</tr>
<tr>
<td>Barrier Methods (condoms, diaphragm)</td>
<td>12-21%</td>
<td>- Must use with every act of intercourse</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Condoms are only method that prevent STI transmission</td>
</tr>
<tr>
<td>Method</td>
<td>Pregnancy Rate in 1 Year</td>
<td>Special Considerations</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lactational amenorrhea method (LAM)</td>
<td>2-8%</td>
<td>- May be impractical for many women</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Must breastfeed infant frequently &amp; exclusively; be amenorrhoeic, and &lt;6 months postpartum</td>
</tr>
<tr>
<td>Fertility awareness-based methods</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>Withdrawal</td>
<td>22%</td>
<td></td>
</tr>
<tr>
<td>Method</td>
<td>Pregnancy Rate in 1 Year</td>
<td>Special Considerations</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lactational amenorrhea method (LAM)</td>
<td>2-8%</td>
<td>- May be impractical for many women</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Must breastfeed infant frequently &amp; exclusively; be amenorrhoeic, and &lt;6 months postpartum</td>
</tr>
<tr>
<td>Fertility awareness-based methods</td>
<td>24%</td>
<td>- Continuation rates are low (47% at 1 year)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Requires active participation by a willing partner</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Requires daily action(s)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Requires lead time to increase effectiveness</td>
</tr>
<tr>
<td>Withdrawal</td>
<td>22%</td>
<td></td>
</tr>
<tr>
<td>Method</td>
<td>Pregnancy Rate in 1 Year</td>
<td>Special Considerations</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>--------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Lactational amenorrhea method (LAM)   | 2-8%                     | - May be impractical for many women  
- Must breastfeed infant frequently & exclusively; be amenorrhoeic, and <6 months postpartum |
| Fertility awareness-based methods     | 24%                      | - Continuation rates are low (47% at 1 year)  
- Requires active participation by a willing partner  
- Requires daily action(s)  
- Requires lead time to increase effectiveness |
| Withdrawal                            | 22%                      | - Continuation rates are low (46% at 1 year)  
- Requires active participation by a willing partner  
- Requires user involvement at each act of intercourse |
### Comparing LARC Methods

<table>
<thead>
<tr>
<th></th>
<th>ParaGard® CopperT 380A</th>
<th>Liletta®</th>
<th>Mirena®</th>
<th>Kyleena®</th>
<th>Skyla®</th>
<th>Nexplanon®</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hormone and Dose</strong></td>
<td>Non-hormonal</td>
<td>52mg LNG (18.6 mcg/day)</td>
<td>52mg LNG (20 mcg/day)</td>
<td>19.5mg LNG (17.5 mcg/day)</td>
<td>13.5mg LNG (14 mcg/day)</td>
<td>68mg ENG (35-45 mcg/day)</td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt; 99%</td>
</tr>
<tr>
<td><strong>FDA-Approved Duration of Use</strong></td>
<td>10 years</td>
<td>6 years</td>
<td>5 years</td>
<td>3 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Expected Bleeding Patterns</strong></td>
<td>Typically heavier</td>
<td>Typically lighter – rates of amenorrhea associated with hormone dose</td>
<td></td>
<td></td>
<td></td>
<td>Typically lighter, often unpredictable</td>
</tr>
</tbody>
</table>

* Ongoing studies suggest high efficacy with extended use beyond FDA-approved durations

©ACOG
Levonorgestrel (LNG) IUD

• Mechanism of action:
  o Prevents fertilization by changing amount and viscosity of cervical mucus, making it impenetrable to sperm

• Does not disrupt pregnancy and is not an abortifacient

• Most women ovulate normally, but experience diminished menstrual bleeding because of the local effect of levonorgestrel on the endometrium

• 99.8% effective; the one-year typical use failure rate is 0.2 per 100 women

©ACOG

Copper IUD

- **Mechanism of action:**
  - Inhibition of sperm migration and viability

- Contains no hormones

- Does not disrupt pregnancy and is not an abortifacient

- The most common adverse effects reported are abnormal bleeding and pain

- 99.2% effective; the one-year typical use failure rate is 0.8 per 100 women

- Most effective method of emergency contraception when inserted within 5 days of unprotected intercourse

©ACOG

Etonogestrel (ENG) implant

- **Mechanism of action:**
  - Primary: ovulation suppression
  - Additional: thickening of cervical mucus and alteration of the endometrial lining

- After implant insertion, changes in bleeding patterns are common and include amenorrhea or infrequent, frequent, or prolonged bleeding

- Placed subdermally in upper arm
  - Size: 4cm x 2mm (comparable in size to a match stick)

- 99.9% effective; the one-year typical use failure rate is 0.05 per 100 women

©ACOG

Troubleshooting Side Effects

• Consider including these tips during counseling so patients can try them before an in-person appointment:
  o Copper IUD
    • To prevent heavy and painful menses: Take ibuprofen 400mg every 4 hours for 7 days starting Day 1 of menses for the first 3-6 cycles
  o LNG-IUD and ENG Implant
    • For unscheduled bleeding: Take naproxen 500mg every 12 hours for 5 days OR ibuprofen 800mg every 8 hours for 5 days

©ACOG

Two postplacental IUD insertion methods

1. Ring forceps
2. Manual/hand

No matter which method, the IUD should always be placed at the fundus of the uterus for both vaginal & cesarean births
IUD removal

- Patients can have an IUD removed at any time upon request
- Prophylactic antibiotics are NOT needed for IUD removal
- Providers should be aware of changes to insurance coverage in the postpartum period that may affect coverage of device removal for patients
- Discuss with the patient:
  - When fertility could return
  - Contraceptive options if pregnancy is not desired
  - Mild uterine cramping and a small amount of bleeding is expected
  - Options for low or no-cost removal services, including Title X or other clinics

©ACOG
Implant follow up

• Immediate postpartum insertion of the contraceptive implant is **identical** to interval insertion and **can be inserted any time after delivery**

• Instruct patient to make a follow up appointment if:
  o Experiencing redness, swelling, or drainage near the implant insertion site
  o Unable feel the implant under their skin

• Bruising and soreness around the insertion site is normal and should resolve within 1-2 weeks

• Providers should be aware of changes to insurance coverage in the postpartum period that may affect coverage of device removal for patients
  o Discuss options for low or no-cost removal services, including Title X or other clinics

©ACOG
Implant removal

• Patients can have an implant removed at any time upon request

• Discuss with the patient:
  o When fertility could return
  o Contraceptive options if pregnancy is not desired

• If the implant is not palpable, pregnancy should be excluded and patients should be offered a method of backup contraception until the implant is located

• The removal process is included in the training required to be provided by Merck, the manufacturer of Nexplanon®, and is not covered in the presentation

• More info & resources: ACOG LARC Program’s Video Series-Implant Removal

©ACOG
IUD EXPULSION

Clinical Considerations
IUD expulsion

• Expulsion rates for immediate postpartum IUD insertions vary by:
  o Study
  o Device type
  o Route of delivery

• Expulsion rates:
  o Immediate postplacental: ~10%
  o 10 minutes to 4 weeks: may be as high as 10-27%

• Continuation rates for IUDs and implants at 1 year are similar with interval placement
IUD expulsion

• Counsel patients about increased risk of expulsion and signs and symptoms of expulsion

• A person who experiences or suspects expulsion should contact their health care provider and use a back-up contraceptive method
IUD expulsion

Key Takeaway:

Many women experience barriers to interval LARC placement, such that the advantages of immediate placement outweigh the disadvantages.

“The immediate postpartum period has several potential benefits for implant insertion or IUD placement because women are known not to be pregnant and many women are motivated to avoid short-interval pregnancy. Additionally, the woman and clinician are in the same place at the same time, which eliminates potential access barriers, including the need for an additional visit and potential loss of insurance coverage postpartum.”

- ACOG Committee Opinion #670, Immediate Postpartum LARC
BREASTFEEDING

Clinical Considerations
Breastfeeding

- The Copper IUD lacks hormones and is classified as CDC MEC Category 1 (no restriction on use) for people who are breastfeeding.

- The LNG IUD and implant are category 2 for theoretical impact on lactation.

- Several small randomized control trials (RCTs) have shown no significant differences in:
  - Breast milk quality or quantity
  - Infant size
Breastfeeding

Key Takeaway:

“Given available evidence, women considering IPP hormonal LARC should be counseled about the theoretical risks of reduced duration of breastfeeding, but the preponderance of evidence has not shown a negative effect on actual breastfeeding outcomes”

- ACOG Practice Bulletin #186, LARC: IUDs & Implants
FOLLOW UP INSTRUCTIONS

for Immediate Postpartum LARC
Postpartum IUD follow-up instructions

• All patients should be **offered** a string check (not mandatory)

• Instruct patient to notify a provider if they have:
  o Fevers, chills, severe abdominal pain, or temperature > 100.4°F
  o Heavy bleeding
  o Pain not controlled by over the counter medicine
  o Expulsion of the device
  o Pain or cramping different from lochia or postpartum cramps
Postpartum implant: follow-up instructions

• Immediate postpartum insertion of the contraceptive implant is **identical** to interval insertion and **can be inserted any time after delivery**

• Instruct patient to make a follow up appointment if:
  - Experiencing redness, swelling, or drainage near the implant insertion site
  - Unable feel the implant under their skin

• Bruising and soreness around the insertion site is normal and should resolve within 1-2 weeks

• Providers should be aware of changes to insurance coverage in the postpartum period and how that may affect coverage of device removal for patients
  - Discuss options for low or no-cost removal services, including Title X or other clinics

©ACOG
KEY TAKEAWAYS

Things to Keep in Mind
Remember the goal! Be person-centered.

- The **goal** of contraceptive counseling is to:
  - Discuss all contraceptive options with patients
  - Have patients leave with a plan for contraception they are comfortable with
  - Allow patients to make the contraceptive choices that are best for them
  - Remind patients that there is not one perfect method for everyone

- **Shared Medical Decision Making:**
  - Focuses on the interpersonal relationship
  - Uses open-ended questions
  - Helps your patient choose the best method for them
  - Takes into account social and cultural contexts

©ACOG
Key Takeaways: Important things to keep in mind

Respect
- Cultural differences
- Personal preferences
- Dislike of method or side effects
- Patient’s decision whether to use birth control after delivery

Listen
- To your patient’s preferences
- To your patient’s concerns
- Shared decision-making is best, but can take time – be patient

Engage
- Allow patient time to consider their options
- Provide information to help patient make a decision
The ACOG LARC Program can help!

- Email us: pcai@acog.org

- Find more resources online:
  - [https://pcainitiative.acog.org](https://pcainitiative.acog.org)

- Send us your LARC-related questions:
  - [www.acoglarc.freshdesk.com](http://www.acoglarc.freshdesk.com)
  - The LARC Program Help Desk is a free service open to all, ACOG members and non-members alike
  - All questions will be responded to within 10 business days.
ACOG guidance on contraceptive counseling

ACOG has many contraceptive counseling resources, including, but not limited to:

1. ACOG Practice Bulletin #186, LARC: Implants and Intrauterine Devices
2. ACOG Committee Opinion #672, Clinical Challenges of LARC Methods
3. ACOG Committee Opinion #670, Immediate Postpartum LARC
4. ACOG Committee Opinion #699, Adolescent Pregnancy, Contraception, and Sexual Activity
5. ACOG Committee Opinion #490, Partnering With Patients to Improve Safety
6. ACOG Committee Opinion #587, Effective Patient-Physician Communication
7. ACOG Committee Opinion #736, Optimizing Postpartum Care
8. Obstetric Care Consensus #8: Interpregnancy Care
ACOG guidance on care for underserved communities

1. ACOG Committee Opinion #729, Importance of Social Determinants of Health and Cultural Awareness in the Delivery of Reproductive Health Care
2. ACOG Committee Opinion #649, Racial and Ethnic Disparities in Obstetrics and Gynecology
3. ACOG Committee Opinion #627, Health Care for Unauthorized Immigrants
4. ACOG Committee Opinion #576, Health Care for Homeless Women
5. ACOG Committee Opinion #547, Health Care for Women in the Military and Women Veterans
6. ACOG Committee Opinion #586, Health Disparities in Rural Women
7. ACOG Committee Opinion #515, Health Care for Urban American Indian and Alaska Native Women
8. ACOG Committee Opinion #708, Improving Awareness of and Screening for Health Risks Among Sex Workers
9. ACOG Committee Opinion #518, Intimate Partner Violence
10. ACOG Committee Opinion #554, Reproductive and Sexual Coercion
11. ACOG Committee Opinion #511, Health Care for Pregnant and Postpartum Incarcerated Women and Adolescent Females
12. ACOG Committee Opinion #535, Reproductive Health Care for Incarcerated Women and Adolescent Females
13. ACOG Committee Opinion #570, Breastfeeding in Underserved Women: Increasing Initiation and Continuation of Breastfeeding
14. ACOG Committee Opinion #496, At-Risk Drinking and Alcohol Dependence: Obstetric and Gynecologic Implication
15. ACOG Committee Opinion #633, Alcohol Abuse and Other Substance Use Disorders: Ethical Issues in Obstetric and Gynecologic Practice
16. ACOG Committee Opinion #591, Challenges for Overweight and Obese Women
QUESTIONS?

List contact information here

DOI: 10.1097/AOG.0b013e318262e354 [doi].
PMID: 22914423.


DOI: 10.1097/AOG.0000000000002045 [doi].
PMID: 28426620.


DOI: S0952818097002584 [pii].
PMID: 9524900.


DOI: 10.1111/1471-0528.13306 [doi].
PMID: 25626730.


DOI: 10.1007/s10995-006-0128-5 [doi].
PMID: 16807794.


DOI: 10.1001/jama.292.2.219 [doi].
PMID: 15249571.

References


DOI: 10.1097/AOG.0000000000001644 [doi].
PMID: 27548557.


DOI: 10.1016/j.contraception.2015.10.001 [doi].
PMID: 26475368.


DOI: 10.1007/s00192-005-1293-6 [doi].
PMID: 15838587.


DOI: S0010-7824(16)30145-7 [pii].
PMID: 27400823.


DOI: 10.15585/mmwr.rr6504a1 [doi].
PMID: 27467319.


DOI: 10.15585/mmwr.rr6503a1 [doi].
PMID: 27467196.


DOI: 10.1016/j.contraception.2011.01.007 [doi].
PMID: 21843688.


DOI: 10.1007/s13669-016-0139-1.
References


References


DOI: 10.1007/BF03027957 [doi].
PMID: 11097535.


DOI: 10.1016/j.contraception.2010.02.002 [doi].
PMID: 20682140.


DOI: 10.1186/1471-2393-9-9 [doi].
PMID: 19250517.


DOI: 10.1097/AOG.0000000000002400 [doi].
PMID: 29064972.


DOI: 10.1002/14651858.CD003036/pub3.
PMID: 28147241.


References


DOI: 10.1097/AOG.0000000000002633 [doi].
PMID: 29683911.


DOI: 10.1097/AOG.0b013e31821d7d60 [doi].
PMID: 21508784.


DOI: 10.1097/AOG.0b013e31821188ad [doi].
PMID: 21508749.


PMID: 26072946.


DOI: S0002-9378(99)70120-1 [pii].
PMID: 10561657.


DOI: 10.1016/j.contraception.2008.12.014 [doi].
PMID: 19501209.


DOI: S0010-7824(05)00109-5 [pii].
PMID: 16246660.

References


DOI: 10.1002/14651858.CD011913.pub2.


DOI: 95/7/1128 [pii].

PMID: 15983269.


DOI: 10.1097/AOG.0b013e3182991db6 [doi].

PMID: 23969798.


DOI: 10.1097/AOG.0b013e3181f73eaa [doi].

PMID: 20966691.


DOI: 10.1016/j.contraception.2011.01.021 [doi].

PMID: 21477680.


DOI: 10.1016/j.contraception.2017.09.014 [doi].

PMID: 28987293.


DOI: 10.1097/AOG.0000000000000841 [doi].

PMID: 26000519.


DOI: 10.1016/j.contraception.2015.09.007 [doi].

PMID: 26408376.
References


DOI: 10.1016/j.ajog.2014.07.059 [doi].
PMID: 25093946.